The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus

Clinical Infectious Diseases

Volumn 44, Issue 9, 2007, Pages 1208-1215

  Tenover, Fred C ^a   Moellering Jr , Robert C ^b  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLINICAL ARTICLE; CLINICAL STUDY; CONCENTRATION RESPONSE; DIFFUSION; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STANDARD; STAPHYLOCOCCUS AUREUS; DRUG EFFECT; MICROBIOLOGICAL EXAMINATION;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 34247282090     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/513203     Document Type: Review

References (51)

1. CLSI. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S15. Wayne, PA: CLSI, 2005.
2. CLSI. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S16. Wayne, PA: CLSI, 2006.
3. Leclercq R, Derlot E, Duval J, et al. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319:157-61.
4. Uttley AH, Collins CH, Naidoo J, et al. Vancomycin-resistant enterococcus. Lancet 1988; 1:57-8.
5. Centers for Disease Control and Prevention. Interim guidelines for prevention and control of Staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Weekly Rep 1997; 46:626-35.
6. Wenzel RP, Edmond MB. Vancomycin-resistant Staphylococcus aureus: infection control considerations. Clin Infect Dis 1998; 27: 245-51.
7. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135-6.
8. Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother 2000; 44: 2276-85.
9. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H, Hiramatsu K. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 1998; 42: 199-209.
10. Smith TI, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340: 493-501.
11. Fridkin SK. Vancomycin-intermediate and - resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001; 32:108-15.
12. Oliveira GA, Dell'Aquila AM, Masiero RL, et al. Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin. Infect Control Hosp Epidemiol 2001; 22:443-8.
13. Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998; 351:1212.
14. Kim MN, Par CH, Woo JH, Ryu JS, Hiramatsu K. Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol 2000; 38: 3879-91.
15. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350:1670-3.
16. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36:1020-7.
17. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. A modified population analysis profile (PAP) method to detect heteroresistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001; 47:399-403.
18. Ariza J, Pujol M, Cabo J, et al. Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 1999; 353: 1587-8.
19. Van Griethuysen A, Van 't Veen A, Buiting A, Walsh T, Kluytmans J. High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in the Netherlands. J Clin Microbiol 2003; 41:2487-91.
20. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. New Engl J Med 2003; 348:1342-7.
21. Rybak M J, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000; 44:1062-6.
22. Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 2004; 53:669-74.
23. Jones RN, Stilwell MG, Sader HS, Fritsche TR, Goldstein BP. Spectrum and potency of dalbavancin tested against 3322 gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn Microbiol Infect Dis 2006; 54:149-53.
24. Tenover FC, Weigel LM, Appelbaum PC, et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 2004; 48:275-80.
25. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus: New York, 2004. MMWR Morb Mortal Wkly Rep 2004; 53:322-3.
26. Madhavan T, Sievert D, Rudrik J, Torresan J, Schulman D. Vancomycin-resistant Staphylococcus aureus infection of a gangrenous toe in a community hospital [abstract 1073]. In: Program and abstracts of the 43rd Annual Meeting of the Infectious Diseases Society of America (San Francisco, CA). Alexandria, VA: Infectious Diseases Society of America, 2005.
27. Carey R, Patel JB, McAllister M, et al. Failure of automated systems to detect vancomycin-resistant Staphylococcus aureus [abstract D-66]. In: Program and abstracts of the 44th International Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2004.
28. Goldstein FW, Kitzis MD. Vancomycin-resistant Staphylococcus aureus: no apocalypse now. Clin Microbiol Infect 2003; 9:761-5.
29. Walsh TR, Bolmstrom A, Qwarnstrom A, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001; 39:2439-414.
30. Sancak B, Ercis S, Menemenlioglu D, Colakoglu S, Hascelik G. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother 2005; 56:519-23.
31. Garnier F, Chainier D, Walsh T, et al. A 1-year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J Antimicrob Chemother 2006; 57: 146-9.
32. Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46:1492-502.
33. Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 2003; 187: 929-38.
34. Sakoulas G, Eliopoulos GM, Fowler VG Jr, et al. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother 2005; 49: 2687-92.
35. Howe RA, Monk A, Wooton M, Walsh TR, Enright MC. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg Infect Dis 2004; 10:855-7.
36. Cui L, Tominaga E, Neoh H, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 1079-82.
37. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr, Eliopoulos G. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50:1581-5.
38. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003; 36:429-39.
39. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38:448-51.
40. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521-8.
41. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC bactericidal activity to efficacy of vancomycin treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398-402.
42. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38:1700-5.
43. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch Intern Med 2006; 166:2138-44.
44. Moore MR, Remington-Perdreau F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 2003; 47:1262-6.
45. European Union Committee on Antimicrobial Susceptibility Testing. Vancomycin/Staphylococcus aureus: antimicrobial wild type distributions of microorganisms - reference database, EUCAST Available at: http://217.70.33.99/Eucast2/SearchController/regShow.jsp?Id=1214. Accessed 12 March 2007.
46. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-97.
47. Rubenstein E, Cammarata SK, Oliphant TH, Wunderink RG; Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-12.
48. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft-tissue infections. Antimicrob Agents Chemother 2005; 49:2260-6.
49. Hageman JC, Liedtke LA, Sunenshine RH, et al. Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants. Clin Infect Dis 2006; 43:e42-5.
50. Kohner, PC, Uhl JR, Cockerill FR III. Staphylococcus aureus cell wall thickness and the relationship to vancomycin resistance: what is VISA? [abstract C-95]. In: Program and abstracts of the 102nd General Meeting of the American Society for Microbiology (Salt Lake City UT). Washington, DC: American Society for Microbiology, 2002.
51. Huang V, Perri M, Vager D, Zervos M. Phenotypic characterization of heterogeneous methicillin-susceptible Staphylococcus aureus correlates to patient outcome [abstract P1457]. In: Program and abstracts of the 16th European Congress of Clinical Microbiology and Infectious Diseases (Nice, France). Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases, 2006.